How is Glycogen Supercompensation Regulated in Human Skeletal Muscle
NCT03458741 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 9
Last updated 2018-03-08
Summary
Nine healthy, moderately fit male volunteers participated in the study. The subjects gave written informed consent after having been informed of any possible risk and discomfort associated with the study. The study was approved by the regional ethics committee in Denmark (Journal number: H-4-2013-071) and performed in accordance with the Declarations of Helsinki II.
All subjects underwent 3 clinical investigations (day 1, day 2 and day 5) during a 5 day glycogen supercompensation regime. The subjects were asked to refrain from physical activity and to eat a controlled diet containing 60% carbohydrates (CHO) for 4 days prior to the initial experiments.
Upon arrival at the laboratory on day 1, the subjects performed one-legged knee extensor exercise for 1 hour at 80% of PWL interspersed by 5 min bouts at 90% of PWL. This was followed by interval exercise until exhaustion containing 4 min bouts starting at 100% PWL followed by 1 min at 50% of PWL. Upon cessation of exercise the subjects showered and rested in the supine position for 4 hours. Then a 120 min hyperinsulinemic euglycemic clamp was initiated by a bolus insulin injection (9.0 mU/kg, Actrapid, Novo Nordisk, Denmark) followed by continuous insulin infusion (1.42 mU/kg/min insulin) reaching a level of plasma insulin around 100 µU/mL (n=9). At least 2 hours before the insulin clamp, catheters were placed in both femoral, one antecubital and one dorsal hand vein. A heat pad was placed around the lower part of the arm and hand in order to "arterialize" blood drawn from the hand vein. Substrate uptake/release across the legs was calculated by multiplying the arterial-venous (AV) difference in blood substrate concentration by femoral arterial blood flow (measured by ultrasound, Philips DICOM). Blood glucose levels were maintained at the euglycemic predefined target by continuously adjusting the glucose infusion rate (GIR) (20% glucose solution; Fresenius Kabi, Sweden). Concurrent measures of substrate AV differences and blood flow were performed every 20 min. Muscle biopsies from m. vastus lateralis were obtained under local anaesthesia (3-5 ml of Xylocaine, 20 mg/ml.) in the basal- and insulin-stimulated state (120 min) by use of needle biopsy technique. Muscle specimen were frozen within 20 sec in liquid nitrogen and stored at -80°C for further analysis. A new incision was made for every biopsy and spaced 4-5 cm apart.
This insulin clamp procedure in combination with basal and insulin stimulated muscle biopsies was repeated in the rested state (without prior exercise) on day 2 and day 5. The subjects arrived in the morning in the overnight fasted state at day 1, day 2 and day 5. During the 5 day supercompensation regime the subjects were provided a predefined isocaloric diet containing 80% carbohydrates, 10% fat and 10% proteins. All food items were handle out to the subjects and compliance of the diet regime was ensured by survey.
Conditions
- Glycogen Depletion
- Insulin Sensitivity
Interventions
- OTHER
-
Glycogen Supercompensation
The subjects arrived in the morning in the overnight fasted state at day 1, day 2 and day 5. Upon arrival in the morning the subjects were given a meal corresponding to 5% of their daily energy intake (\~600-800 kJ). During the 5 day supercompensation regime the subjects were provided a predefined isocaloric diet containing 80% carbohydrates, 10% fat and 10% proteins. All food items were handle out to the subjects and compliance of the diet regime was ensured by survey.
Sponsors & Collaborators
-
University of Copenhagen
lead OTHER
Study Design
- Purpose
- BASIC_SCIENCE
- Masking
- NONE
- Model
- SEQUENTIAL
Eligibility
- Min Age
- 25 Years
- Max Age
- 30 Years
- Sex
- MALE
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2013-09-05
- Primary Completion
- 2014-12-31
- Completion
- 2014-12-31
Countries
- Denmark
Study Locations
More Related Trials
-
Is Insulin Resistance and/or Glucose Intolerance Pathogenetic in the Development of a Reduced Incretin Effect
NCT00784745 ·Status: COMPLETED ·Phase: NA
-
Glucagon and Advanced HCL System to Prevent Exercise-Induced Hypoglycaemia in People With Type 1 Diabetes
NCT05379686 ·Status: COMPLETED ·Phase: NA
-
Glucagon Efficiency After High and Low Carbohydrate Diet
NCT02578498 ·Status: COMPLETED ·Phase: PHASE4
-
The Effect of Metformin in Overweight Patients With Dysregulated Type 1 Diabetes Mellitus
NCT00145379 ·Status: COMPLETED ·Phase: PHASE4
-
The Anatomical Location, Cellular Origin and Molecular Basis of Gut-derived Glucagon Secretion
NCT03181191 ·Status: COMPLETED ·Phase: NA
-
Oral Glucose Stimulation in Normal-weight and Obese Volunteers
NCT01875575 ·Status: COMPLETED ·Phase: NA
-
A Glucometabolic Evaluation of Patients With Idiopathic Ketotic Hypoglycemia
NCT05310292 ·Status: UNKNOWN ·Phase: NA
-
Hyperglucagonaemia in Patients With Type 2 Diabetes - Role of Glucagon Clearance
NCT02475421 ·Status: COMPLETED ·Phase: NA
-
The Role of GLP-1 Receptor Signalling in the Glucose-lowering Effect of Metformin in Patients With T2D
NCT03246451 ·Status: COMPLETED ·Phase: NA
-
Incretin Hormones in Type-1 Diabetes Mellitus Glycemic Response in Type-1 Diabetes Mellitus
NCT00832741 ·Status: COMPLETED
-
Glucagon Responses During Oral- and iv Glucose in Patients With Type 1 Diabetes
NCT00704795 ·Status: UNKNOWN
-
Metabolic Signalling in Muscle- and Adipose-tissue Following Insulin Withdrawal and Growth Hormone Injection.
NCT02077348 ·Status: COMPLETED ·Phase: NA
-
Low Glycemic Index Diet in Patients With Type 1 Diabetes
NCT01184703 ·Status: COMPLETED ·Phase: PHASE3
-
Intracellular Counter-regulatory Mechanisms Following Low Blood Glucose
NCT01919788 ·Status: COMPLETED ·Phase: NA
-
The Role of Glucose-Dependent Insulinotropic Polypeptide in the Pathological Glucose Homeostasis Of Type 1 Diabetes
NCT03734718 ·Status: COMPLETED ·Phase: NA
-
Efficacy of Glucagon In the Prevention of Hypoglycemia During Mild Exercise
NCT03217175 ·Status: TERMINATED ·Phase: NA
-
Inhibition of the Endogenous GIP Response With a GIP Receptor Antagonist
NCT03133741 ·Status: COMPLETED ·Phase: NA
-
Metformin to Prevent Metabolic Complications in Glucocorticoid Excess
NCT01187849 ·Status: COMPLETED ·Phase: PHASE4
-
The Effect of Insulin-induced Hypoglycaemia on Gut-derived Glucagon Secretion (Px-Hypo)
NCT04064203 ·Status: COMPLETED ·Phase: NA
-
Hepatic Metabolic Changes in Response to Glucagon Infusion
NCT03526445 ·Status: COMPLETED ·Phase: NA
-
Examination of the Postprandial Bone Remodeling in Persons With Reduced GIP-Receptor Activity
NCT02518737 ·Status: COMPLETED
-
Treatment of Low Blood Sugar With Glucagon Among Patients With Type 1 Diabetes
NCT02232971 ·Status: UNKNOWN ·Phase: PHASE4
-
Near Normalisation of BG Improves the Potentiating Effect of GLP-1
NCT00612625 ·Status: COMPLETED ·Phase: NA
-
Glucotoxicity and Acute Exercise
NCT01771614 ·Status: WITHDRAWN ·Phase: NA
-
IGF-I Induced Muscle Glucose Uptake and Interstitial IGF-I Concentrations
NCT01588093 ·Status: COMPLETED ·Phase: NA